102 related articles for article (PubMed ID: 24530897)
1. Modification of FP-HIV activity by peptide sequences of GB virus C: a biophysical approach.
Domènech O; Ortiz A; Pujol M; Haro I; Muñoz M; Alsina MA; Prat J; Busquets MA; Girona V
Biochim Biophys Acta; 2014 May; 1838(5):1274-80. PubMed ID: 24530897
[TBL] [Abstract][Full Text] [Related]
2. Study of the inhibition capacity of an 18-mer peptide domain of GBV-C virus on gp41-FP HIV-1 activity.
Haro I; Gómara MJ; Galatola R; Domènech O; Prat J; Girona V; Busquets MA
Biochim Biophys Acta; 2011 Jun; 1808(6):1567-73. PubMed ID: 21377446
[TBL] [Abstract][Full Text] [Related]
3. Effect of E1(64-81) hepatitis G peptide on the in vitro interaction of HIV-1 fusion peptide with membrane models.
Sánchez-Martín MJ; Busquets MA; Girona V; Haro I; Alsina MA; Pujol M
Biochim Biophys Acta; 2011 Sep; 1808(9):2178-88. PubMed ID: 21672514
[TBL] [Abstract][Full Text] [Related]
4. Surface behavior of peptides from E1 GBV-C protein: Interaction with anionic model membranes and importance in HIV-1 FP inhibition.
Galatola R; Cruz A; Gómara MJ; Prat J; Alsina MA; Haro I; Pujol M
Biochim Biophys Acta; 2015 Feb; 1848(2):392-407. PubMed ID: 25450346
[TBL] [Abstract][Full Text] [Related]
5. Biophysical investigations of GBV-C E1 peptides as potential inhibitors of HIV-1 fusion peptide.
Sánchez-Martín MJ; Urbán P; Pujol M; Haro I; Alsina MA; Busquets MA
Chemphyschem; 2011 Oct; 12(15):2816-22. PubMed ID: 21905195
[TBL] [Abstract][Full Text] [Related]
6. Synthetic peptides of hepatitis G virus (GBV-C/HGV) in the selection of putative peptide inhibitors of the HIV-1 fusion peptide.
Herrera E; Gomara MJ; Mazzini S; Ragg E; Haro I
J Phys Chem B; 2009 May; 113(20):7383-91. PubMed ID: 19402654
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 fusion is blocked through binding of GB Virus C E2-derived peptides to the HIV-1 gp41 disulfide loop [corrected].
Eissmann K; Mueller S; Sticht H; Jung S; Zou P; Jiang S; Gross A; Eichler J; Fleckenstein B; Reil H
PLoS One; 2013; 8(1):e54452. PubMed ID: 23349893
[TBL] [Abstract][Full Text] [Related]
8. The helix-to-sheet transition of an HIV-1 fusion peptide derivative changes the mechanical properties of lipid bilayer membranes.
Heller WT; Zolnierczuk PA
Biochim Biophys Acta Biomembr; 2019 Mar; 1861(3):565-572. PubMed ID: 30550881
[TBL] [Abstract][Full Text] [Related]
9. Liposome destabilization induced by synthetic lipopeptides corresponding to envelope and non-structural domains of GBV-C/HGV virus. Conformational requirements for leakage.
Fernández-Vidal M; Rojo N; Herrera E; Gómara MJ; Haro I
Biophys Chem; 2008 Jan; 132(1):55-63. PubMed ID: 17988786
[TBL] [Abstract][Full Text] [Related]
10. Effects of overlapping GB virus C/hepatitis G virus synthetic peptides on biomembrane models.
Larios C; Busquets MA; Carilla J; Alsina MA; Haro I
Langmuir; 2004 Dec; 20(25):11149-60. PubMed ID: 15568870
[TBL] [Abstract][Full Text] [Related]
11. Fatty acids can substitute the HIV fusion peptide in lipid merging and fusion: an analogy between viral and palmitoylated eukaryotic fusion proteins.
Lev N; Shai Y
J Mol Biol; 2007 Nov; 374(1):220-30. PubMed ID: 17919659
[TBL] [Abstract][Full Text] [Related]
12. Analysis of HIV-1 fusion peptide inhibition by synthetic peptides from E1 protein of GB virus C.
Sánchez-Martín MJ; Hristova K; Pujol M; Gómara MJ; Haro I; Alsina MA; Busquets MA
J Colloid Interface Sci; 2011 Aug; 360(1):124-31. PubMed ID: 21565353
[TBL] [Abstract][Full Text] [Related]
13. HIV fusion peptide penetrates, disorders, and softens T-cell membrane mimics.
Tristram-Nagle S; Chan R; Kooijman E; Uppamoochikkal P; Qiang W; Weliky DP; Nagle JF
J Mol Biol; 2010 Sep; 402(1):139-53. PubMed ID: 20655315
[TBL] [Abstract][Full Text] [Related]
14. A cyclic GB virus C derived peptide with anti-HIV-1 activity targets the fusion peptide of HIV-1.
Galatola R; Vasconcelos A; Pérez Y; Cruz A; Pujol M; Alsina MA; Gómara MJ; Haro I
Eur J Med Chem; 2014 Oct; 86():589-604. PubMed ID: 25218908
[TBL] [Abstract][Full Text] [Related]
15. HIV fusion inhibitor peptide T-1249 is able to insert or adsorb to lipidic bilayers. Putative correlation with improved efficiency.
Veiga AS; Santos NC; Loura LM; Fedorov A; Castanho MA
J Am Chem Soc; 2004 Nov; 126(45):14758-63. PubMed ID: 15535700
[TBL] [Abstract][Full Text] [Related]
16. Permeabilization and fusion of uncharged lipid vesicles induced by the HIV-1 fusion peptide adopting an extended conformation: dose and sequence effects.
Pereira FB; Goñi FM; Muga A; Nieva JL
Biophys J; 1997 Oct; 73(4):1977-86. PubMed ID: 9336193
[TBL] [Abstract][Full Text] [Related]
17. Behaviour of a peptide sequence from the GB virus C/hepatitis G virus E2 protein in Langmuir monolayers: its interaction with phospholipid membrane models.
Pérez-López S; Nieto-Suárez M; Mestres C; Alsina MA; Haro I; Vila-Romeu N
Biophys Chem; 2009 May; 141(2-3):153-61. PubMed ID: 19232456
[TBL] [Abstract][Full Text] [Related]
18. Interaction of GB virus C/hepatitis G virus synthetic peptides with lipid langmuir monolayers and large unilamellar vesicles.
Pérez-López S; Vila-Romeu N; Asunción Alsina Esteller M; Espina M; Haro I; Mestres C
J Phys Chem B; 2009 Jan; 113(1):319-27. PubMed ID: 19195104
[TBL] [Abstract][Full Text] [Related]
19. Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection.
Herrera E; Tenckhoff S; Gómara MJ; Galatola R; Bleda MJ; Gil C; Ercilla G; Gatell JM; Tillmann HL; Haro I
J Med Chem; 2010 Aug; 53(16):6054-63. PubMed ID: 20718496
[TBL] [Abstract][Full Text] [Related]
20. Conformational mapping of the N-terminal peptide of HIV-1 gp41 in membrane environments using (13)C-enhanced Fourier transform infrared spectroscopy.
Gordon LM; Mobley PW; Pilpa R; Sherman MA; Waring AJ
Biochim Biophys Acta; 2002 Feb; 1559(2):96-120. PubMed ID: 11853678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
